Mirataz™(mirtazapine transdermal ointment)
Mirataz is transdermal mirtazapine, formulated with KindredBio’s proprietary Accusorb™ technology, being developed for the management of weight loss in cats.
1 U.S. Veterinarian Mirtazapine Phase 2 Research, Wise Insights, May 2016 (n=89 U.S. small animal veterinarians). U.S. Veterinarian Mirtazapine Phase Research, Ipsos, September 2016 (n=201 U.S. small animal veterinarians). Data on file at KindredBio.
2 Freeman LM et al. Evaluation of weight loss over time in cats with chronic kidney disease. J Vet Int Med. 2016; 30:1661-1666.
3 Agnew W and Kirman R. Pharmacological appetite stimulation: rationale choices in the inappetent cat. J Feline Med Surg. 2014;16(9):749-56.
4 Quimby JM and Lunn KE. Mirtazapine as an appetite stimulant and anti-emetic in cats with chronic kidney disease: a masked placebo-controlled crossover clinical trial. Vet J. 2013;197(3):651-5.
5 Benson KK et al. Drug exposure and clinical effect of transdermal mirtazapine in healthy young cats: a pilot study. J Fel Med Surg. 2017;19(10):998-1006.